- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05195450
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load - a Randomized Controlled Trial
The main goal of therapy for patients with chronic HBV infection with no significant liver disease is to improve survival and quality of life by preventing disease progression, development of liver cirrhosis and consequently HCC development. The likelihood of achieving these goals depends on the timing of therapy during the natural course of the infection but also on the stage of the disease and the patients' age when treatment is started. The inhibition of viral replication and normalization of ALT by antiviral treatment has been shown to achieve the elimination of chronic HBV-induced necroinflammatory activity and progressive fibrotic liver progression in the vast majority of patients, in turn reducing the risk of HCC. Even in HBeAg positive patients, treatment-induced HBeAg loss and seroconversion to antiHBe characterizes the induction of a partial immune control often leading to a low replicative phase of the chronic HBV infection and good outcomes.
Treatment in chronic HBV infection is indicated in - presence of advanced fibrosis/cirrhosis (LSM >11 KPA) or patients with significant fibrosis (LSM >8 or APRI >1.5 or >F2 on liver biopsy) with high viral load (>2000 IU/ml) or significantly elevated ALT (x2 ULN). Presence of any of these factors is known to increase the risk of development of cirrhosis and hepatocellular carcinoma. TAF in non-cirrhotic patients (LSM <8 KPA) with normal ALT and low viral load (HBV DNA <2000 IU/ml) (currently treatment ineligible) as compared to delayed initiation (on demand) might reduce HCC risk, progression of liver fibrosis and reduction in HBsAg levels. As TAF is known to have favorable effects on the overall long-term outcome, the main clinical challenge is to identify the patients at risk of HCC and cirrhosis who warrant early antiviral therapy.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Aim and Objective - To study the safety and efficacy of TAF as compared to initiation based on current criteria in patients with non-cirrhotic chronic HBV infection and normal ALT and low viral load.
Methodology:
Study population: The study will be conducted on the treatment naïve consecutive patients having non-cirrhotic chronic HBV infection and normal ALT and low viral load seen at the outpatient clinics/wards of Department of Hepatology, ILBS, New Delhi.
Study design:
• A prospective, randomized, single center open label study.
Study period: 5 years from the last patient enrollment
Sample size with justification: All consecutive cases consenting to be a participant in this study and meeting inclusion and exclusion criteria will be enrolled. Considering the incidence of 20% for the composite end-point in patients without TAF and 5% for patients on TAF, with power of 80% and alpha error of 5%, 176 patients (88 patients in each arm) need to be enrolled. Considering the attrition rate of ~15%, we decide to enroll 100 patients in each arm.
Intervention
- TAF 25 mg OD vs no treatment x 5 years and beyond
- Tests - Baseline - USG abdomen, ALT, Creatinine, DEXA, HBVDNA, HBeAg, HBsAg (quant), Fibroscan
- 6 monthly - ALT
- 1 yearly - USG abdomen, ALT, Creatinine, DEXA, HBVDNA, HBeAg, HBsAg (quant), Fibroscan
- No liver biopsy
Statistical Analysis:
Data will be reported as mean + SD. Categorical variables will be compared using the chi-square test or Fisher exact test. Normal continuous variables will be compared using the Student's t test Non normal continuous variables will be compared using the Mann Whitney rank-sum test (unpaired data) or the Wilcoxon test (paired data). The actuarial probability of survival will be calculated by the Kaplan-Meier method and compared using the log-rank test. A Cox regression analysis will be performed to identify independent prognostic factors for survival. Univariate and multivariate analysis will be used whenever applicable.
Adverse effects:
Most common- headache, nausea, and fatigue; (1% to 10%): Abdominal pain, nausea, diarrhea, dyspepsia, elevated serum amylase, vomiting, flatulence, abdominal distension; Common (1% to 10%): Rash, pruritus, elevated ALT; Uncommon (0.1% to 1%): Treatment ALT flares.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Dr Ankur Jindal, DM
- Telefonnummer: 01146300000
- E-mail: ankur.jindal3@gmail.com
Studiesteder
-
-
Delhi
-
New Delhi, Delhi, Indien, 110070
- Rekruttering
- Institute of Liver & Biliary Sciences (ILBS)
-
Kontakt:
- Dr Ankur Jindal, DM
- Telefonnummer: 01146300000
- E-mail: ankur.jindal3@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- HBsAg+
- Persistent normal ALT 3-6m apart (<30 IU/ml in male and <20 IU/ml in female)
- HBV DNA < 2000 IU/ml
- LSM <8 Kpa
Exclusion Criteria:
- Prior NUC/IFN exposure
- Renal dysfunction (Serum Creatinine >1.5 mg/dl)
- Known liver cirrhosis/ esophageal varices
- Any clinical decompensation (CD)
- Pre-existing hepatocellular carcinoma
- Pregnancy
- Healthcare workers (HCW)
- Post transplant, patients with advance malignancy or on chemotherapy
- Co-infections - Hepatitis C, Hepatitis D, Human immunodeficiency virus
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Tenofovir Alafenamide Fumarate
• TAF 25 mg OD vs no treatment x 5 years and beyond
|
• TAF 25 mg OD vs no treatment x 5 years and beyond
|
Ingen indgriben: No Treatment Arm
No treatment
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of patients with HBV DNA <2000 IU/ml, normal ALT and no significant fibrosis (as per APASL 2015).
Tidsramme: upto 5 Years
|
Any two of the following -
|
upto 5 Years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Incidence of HCC
Tidsramme: upto 3 years
|
upto 3 years
|
Incidence of HCC
Tidsramme: upto 5 years
|
upto 5 years
|
Percentage of patients with LSM >8 Kpa
Tidsramme: upto 5 Years
|
upto 5 Years
|
Percentage of patients with LSM >11 Kpa
Tidsramme: upto 5 Years
|
upto 5 Years
|
Number of subjects with no progression of fibrosis
Tidsramme: upto 5 Years
|
upto 5 Years
|
Percentage of patients with APRI score >1.5 and >2
Tidsramme: upto 5 Years
|
upto 5 Years
|
Percentage of patients with HBV DNA >2000 IU/ml
Tidsramme: upto 5 Years
|
upto 5 Years
|
Percentage of patients with undetectable HBV DNA
Tidsramme: upto 5 Years
|
upto 5 Years
|
Percentage of patients with HBsAg loss and HBsAg seroconversion
Tidsramme: upto 5 Years
|
upto 5 Years
|
Log HBsAg reduction
Tidsramme: upto 5 Years
|
upto 5 Years
|
Percentage of patients with HBeAg loss and HBeAg seroconversion in HBeAg+ chronic hepatitis B
Tidsramme: upto 5 Years
|
upto 5 Years
|
Percentage of patients with ALT > ULN, >2 times and 5 times ULN
Tidsramme: upto 5 Years
|
upto 5 Years
|
Treatment related adverse effects of TAF
Tidsramme: upto 5 Years
|
upto 5 Years
|
Non-compliant to treatment or monitoring
Tidsramme: upto 5 years
|
upto 5 years
|
Death
Tidsramme: upto 5 years
|
upto 5 years
|
Treatment related severe adverse effects
Tidsramme: upto 5 years
|
upto 5 years
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Hepatitis, viral, menneskelig
- Hepadnaviridae infektioner
- DNA-virusinfektioner
- Hepatitis, kronisk
- Hepatitis
- Leversygdomme
- Hepatitis B
- Hepatitis B, kronisk
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Reverse transkriptasehæmmere
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Anti-HIV-midler
- Anti-retrovirale midler
- Tenofovir
Andre undersøgelses-id-numre
- ILBS-HBV-02
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Non-cirrhotic, Chronic Hepatitis B
-
Fudan UniversityUkendtNon-Hodgkin lymfom | Reaktivering af hepatitis BKina
-
ANRS, Emerging Infectious DiseasesUkendtKronisk hepatitis CFrankrig
-
Sun Yat-sen UniversityRekrutteringLøst hepatitis B | CD20 Positivt B-celle lymfomKina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesIkke rekrutterer endnu
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UkendtKronisk hepatitis b
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu... og andre samarbejdspartnereRekrutteringKronisk hepatitis b | Reaktivering af hepatitis BTaiwan
-
Mahidol UniversityUkendtKronisk Hepatitis B, HBsAg, Hepatitis B-vaccineThailand
-
Tongji HospitalGilead SciencesRekruttering
-
Jiangsu HengRui Medicine Co., Ltd.Ukendt
-
Changhai HospitalAfsluttet
Kliniske forsøg med Tenofovir alafenamide fumarate
-
Nucorion Pharmaceuticals, Inc.Ligand PharmaceuticalsAfsluttetKronisk hepatitis BForenede Stater
-
Jiangsu Aidea Pharmaceutical Co., LtdChengdu Aidea Pharmaceutical Technology Co., LtdRekruttering
-
SpectraCure ABRekrutteringTilbagevendende prostatakræftForenede Stater, Canada, Det Forenede Kongerige, Sverige
-
Zhongshan Hospital (Xiamen), Fudan UniversityRekrutteringHepatocellulært karcinom | Kronisk hepatitis BKina
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)AfsluttetOndartet fast neoplasma | Hepatitis B infektionForenede Stater, Guam
-
University Hospital Inselspital, BerneAfsluttet
-
Kaohsiung Medical University Chung-Ho Memorial...UkendtHepatitis B | Fibrose og skrumpeleverTaiwan
-
University Health Network, TorontoGilead Sciences; University of Modena and Reggio Emilia; San Raffaele University... og andre samarbejdspartnereAfsluttetOvergangsalderen | HIV | OsteoporoseCanada, Italien
-
Young-Suk LimSamsung Medical Center; Seoul National University Hospital; Korea University... og andre samarbejdspartnereAfsluttetKronisk hepatitis bKorea, Republikken
-
Massachusetts General HospitalGilead SciencesTrukket tilbageTræthed | Multipel sklerose, recidiverende-remitterendeForenede Stater